The ASCEND Study: Gemcitabine and Nab-Paclitaxel With CEND-1 or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma (ASCEND)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05042128 |
|
Recruitment Status :
Recruiting
First Posted : September 13, 2021
Last Update Posted : January 26, 2023
|
Sponsor:
Australasian Gastro-Intestinal Trials Group
Collaborator:
University of Sydney
Information provided by (Responsible Party):
Australasian Gastro-Intestinal Trials Group
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of the ASCEND clinical trial is to measure the effect of adding CEND-1, compared to placebo, to chemotherapy (gemcitabine and nab-paclitaxel) in patients who have untreated metastatic pancreatic cancer. The study will assess the duration which the cancer remained stable or improved, the number of patients who responded to treatment, overall survival, side effects and quality of life.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Pancreatic Ductal Adenocarcinoma Metastatic Pancreatic Cancer | Drug: CEND-1 Drug: Gemcitabine Injection Drug: Nab paclitaxel | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 125 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Care Provider) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomised, Double-blinded Phase II Study of Gemcitabine and Nab-Paclitaxel With CEND-1 or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma |
| Actual Study Start Date : | April 13, 2022 |
| Estimated Primary Completion Date : | October 1, 2024 |
| Estimated Study Completion Date : | October 1, 2024 |
Resource links provided by the National Library of Medicine
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Standard Care + CEND1
Participants will receive nab-paclitaxel 125mg/m2; CEND1 3.2mg/kg IV; and then Gemcitabine 1000mg/m2, on Day 1, 8 and 15 of each cycle. Each cycle will be 28 days.
|
Drug: CEND-1
CEND-1 is a novel cyclic tumour-penetrating peptide iRGD (internalizing Arginylglycylaspartic acid) which may overcome poor drug delivery by activation of a complex trans-tissue transport pathway, providing an opportunity to overcome this mechanism of resistance in PDAC
Other Name: iRGD Drug: Gemcitabine Injection Chemotherapy drug provided as solution to be administered via IV infusion.
Other Name: Gemzar Drug: Nab paclitaxel Chemotherapy drug provided as solution to be administered via IV infusion.
Other Name: Abraxane |
|
Placebo Comparator: Standard Care + Placebo
Participants will receive nab-paclitaxel 125mg/m2; placebo IV; and then Gemcitabine 1000mg/m2, on Day 1, 8 and 15 of each cycle. Each cycle will be 28 days.
|
Drug: Gemcitabine Injection
Chemotherapy drug provided as solution to be administered via IV infusion.
Other Name: Gemzar Drug: Nab paclitaxel Chemotherapy drug provided as solution to be administered via IV infusion.
Other Name: Abraxane |
Primary Outcome Measures :
- Progression Free Survival [ Time Frame: From date of randomization to 18 months later, or death ]Period of time from randomization to the date of first evidence of disease progression, the occurrence of new disease or death from any cause
Secondary Outcome Measures :
- Overall Survival [ Time Frame: From date of randomization to 18 months later, or death ]Period of time from randomization to date of death from any cause, or the date of last known follow-up alive
- Objective Tumour Response Rate [ Time Frame: From date of randomization to 18 months later, or death ]The number of participants with documented partial or complete response (PR or CR) divided by the number of participants evaluable for response as defined as per the RECIST version 1.1 criteria
- Patient-reported Outcomes [ Time Frame: Completed at baseline, then every 8 weeks from randomization until and at disease progression (to a maximum of 48 months). ]Completion of the EORTC QLQ-C30 questionnaire. 30 questions; 28 on a 1-4 scale (Higher scores indicative of poorer quality of life), 2 on a 1-7 scale (higher scores indicative of better health/quality of life).
- Patient-reported Outcomes [ Time Frame: Completed at baseline, then every 8 weeks from randomization until and at disease progression (to a maximum of 48 months). ]Completion of the QLQ-PAN26 questionnaire. 26 questions on a 1-4 scale (Higher scores indicative of poorer quality of life)
- Incidence of Treatment-Emergent Adverse Events (Patient Safety) [ Time Frame: From date of randomization until 30 days after final treatment visit ]Record of all adverse events (including SAEs) that patients experience
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Adults, 18 years or older with histologically confirmed metastatic pancreatic ductal adenocarcinoma or poorly differentiated carcinoma.
- Measurable disease according to RECIST 1.1.
- Archival tumour tissue for tertiary correlative studies (biopsy or resection of primary or metastasis). Fine needle aspirate (FNA) or brushings will not be accepted.
- ECOG performance of 0-1 (Appendix 2)
- Adequate renal and haematological function
- Adequate hepatic function, defined as:
Bilirubin <1.5 X ULN (Upper Limit of Normal), AST or ALT ≤ 5x ULN. If a person was recently stented with improving bilirubin, the person can be randomised with bilirubin up to 3 x ULN provided chemotherapy is not administered until within the stated thresholds.
- Willing and able to comply with all study requirements, including treatment, timing and/or nature of required assessments.
- Study treatment both planned and able to start within 7 days after randomisation
- Signed, written informed consent.
Exclusion Criteria:
- Uncontrolled metastatic disease to the central nervous system. To be eligible, known CNS metastases should have been treated with surgery and/or radiotherapy and the patient should have been receiving a stable dose of steroids for at least 2 weeks prior to randomisation, with no deterioration in neurological symptoms during this time.
- Prior chemotherapy or investigational anti-cancer therapy for metastatic pancreatic adenocarcinoma. Prior treatments with curative intent or for locally advanced disease are allowed, provided the last dose of chemotherapy was administered more than 6 months prior to randomisation.
- Prior radiotherapy or major surgery (as defined by local investigator) within 14 days of starting treatment.
- Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anti-cancer therapy with the exception of alopecia, vitiligo and the laboratory values defined in the inclusion criteria. Participants with Grade ≥2 peripheral neuropathy are not allowed.
- Concurrent use of any other anti-cancer therapy including chemotherapy, targeted therapy, immunotherapy or biological agents.
- Known allergy or hypersensitivity to any of the study drugs and excipients.
- Any significant active infection, including chronic active hepatitis B, hepatitis C, or HIV. Participants with known Hepatitis B/C infection will be allowed to participate providing evidence of viral suppression has been documented and the patient remains on appropriate anti-viral therapy.
-
History of prior or synchronous malignancy within 2 years prior to randomisation, except:
- Malignancy that was treated with curative intent and for which there has been no known active disease for ≥2 years prior to randomisation.
- Curatively treated non-melanoma skin cancer, cervical cancer in situ, superficial transitional cell carcinoma of the bladder, stage 1 endometrial carcinoma, prostatic intraepithelial neoplasia, low-grade papillary thyroid cancer, untreated localised very low risk or low risk prostate cancer under observation.
- Concurrent illness, including severe infection that may jeopardise the ability of the person to undergo the procedures outlined in this protocol with reasonable safety.
- Neuroendocrine pancreatic carcinoma.
- Life expectancy of less than 3 months.
- Pregnancy, lactation, or inadequate contraception. Women must be post-menopausal, infertile, or use a reliable means of contraception. Women of childbearing potential must have a negative pregnancy test done within 7 days prior to randomisation. Men must use a reliable means of contraception.
- Serious medical or psychiatric conditions that might limit the ability of the person to comply with the protocol.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05042128
Contacts
| Contact: Nathan Bradshaw | +61280365270 | ascend.study@sydney.edu.au |
Locations
Show 21 study locations
Sponsors and Collaborators
Australasian Gastro-Intestinal Trials Group
University of Sydney
Investigators
| Study Chair: | Andrew Dean | St John of God Hospital | |
| Study Chair: | Timothy Price | The Queen Elizabeth Hospital |
Publications:
Dean A, Gill S, McGregor M, et al. 1528P Phase I trial of the first-in-class agent CEND-1 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer. Annals of Oncology 2020; 31: S941.
| Responsible Party: | Australasian Gastro-Intestinal Trials Group |
| ClinicalTrials.gov Identifier: | NCT05042128 |
| Other Study ID Numbers: |
CTC0304 |
| First Posted: | September 13, 2021 Key Record Dates |
| Last Update Posted: | January 26, 2023 |
| Last Verified: | January 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Adenocarcinoma Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Gemcitabine Paclitaxel Antineoplastic Agents, Phytogenic Antineoplastic Agents Tubulin Modulators Antimitotic Agents |
Mitosis Modulators Molecular Mechanisms of Pharmacological Action Antimetabolites, Antineoplastic Antimetabolites Antiviral Agents Anti-Infective Agents Enzyme Inhibitors Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs |